Mobile site search icon.
Mobile navigation icon.

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

CONNECT WITH A TAKEDA HAE REPRESENTATIVE

Please complete and submit this form and a representative in your area will contact you.

All fields are required.

Preferred contact method

Your privacy is important to us. For more information, please refer to our Privacy Notice. To manage your communication preferences visit our preference center.

By providing your information you certify that you are a healthcare provider.